Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
Hiruma S, Shigiyama F, Hisatake S, Mizumura S, Shiraga N, Hori M, Ikeda T, Hirose T, Kumashiro N. Hiruma S, et al. Among authors: shigiyama f. Cardiovasc Diabetol. 2021 Feb 2;20(1):32. doi: 10.1186/s12933-021-01228-3. Cardiovasc Diabetol. 2021. PMID: 33530982 Free PMC article. Clinical Trial.
Characteristics of hepatic insulin-sensitive nonalcoholic fatty liver disease.
Shigiyama F, Kumashiro N, Furukawa Y, Funayama T, Takeno K, Wakui N, Ikehara T, Nagai H, Taka H, Fujimura T, Uchino H, Tamura Y, Watada H, Nemoto T, Shiraga N, Sumino Y, Hirose T. Shigiyama F, et al. Hepatol Commun. 2017 Jul 29;1(7):634-647. doi: 10.1002/hep4.1077. eCollection 2017 Sep. Hepatol Commun. 2017. PMID: 29404483 Free PMC article.
Efficacy of intermittent empagliflozin supplementation on dietary self-management and glycaemic control in patients with poorly controlled type 2 diabetes: A 24-week randomized controlled trial.
Yoshikawa F, Kumashiro N, Shigiyama F, Uchino H, Ando Y, Yoshino H, Miyagi M, Ikehara K, Hirose T. Yoshikawa F, et al. Among authors: shigiyama f. Diabetes Obes Metab. 2019 Feb;21(2):303-311. doi: 10.1111/dom.13524. Epub 2018 Oct 5. Diabetes Obes Metab. 2019. PMID: 30187632 Clinical Trial.
Sustained fasting glucose oxidation and postprandial lipid oxidation associated with reduced insulin dose in type 2 diabetes with sodium-glucose cotransporter 2 inhibitor: A randomized, open-label, prospective study.
Kanazawa K, Uchino H, Shigiyama F, Igarashi H, Ikehara K, Yoshikawa F, Usui S, Miyagi M, Yoshino H, Ando Y, Kumashiro N, Hirose T. Kanazawa K, et al. Among authors: shigiyama f. J Diabetes Investig. 2019 Jul;10(4):1022-1031. doi: 10.1111/jdi.12994. Epub 2019 Feb 19. J Diabetes Investig. 2019. PMID: 30582774 Free PMC article. Clinical Trial.
25 results